The results suggest that NEDD4L is able to inhibit cell viability, cell cycle progression, and glutamine metabolism in ESCC by inducing the ubiquitination degradation of c-Myc and reducing the expression of glutaminase (GLS1) and solute carrier family 1 member 5 (SLC1A5). Here, GLS is linked to esophageal squamous cell carcinoma.